RxDoctor Payments Data

Mark Bigda, DO

Internal Medicine · Easthampton, MANPI 1043292089

Payments from drug & device makers

$1,460in general payments, 2019–2025

Across 71 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$231
  • Abbott$223
  • GSK$194
  • Lundbeck LLC$158
  • Exact Sciences$140
  • Pfizer$134
  • plus $379 from 7 others

What the payments were for

  • Food & beverage$1,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,460 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$179,332
Medicare patients
494
Services billed
2,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$113,009
TrulicityDulaglutide98$105,303
OzempicSemaglutide63$86,323
JardianceEmpagliflozin94$75,361
XareltoRivaroxaban38$32,938
Breo ElliptaFluticasone/Vilanterol42$27,097
Bydureon BciseExenatide Microspheres31$25,494
MounjaroTirzepatide18$23,675
JanuviaSitagliptin Phosphate29$22,732
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$18,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,001
EntrestoSacubitril/Valsartan17$16,741
TradjentaLinagliptin23$10,723
Aripiprazole13$8,006
Humalog Kwikpen U-100Insulin Lispro21$5,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$231$128,978116 claims
PfizerEliquis$134$113,009130 claims
Novo NordiskOzempic$95$86,32363 claims
GSKBreo Ellipta, Trelegy Ellipta$194$45,09863 claims
Johnson & JohnsonXarelto$101$32,93838 claims
AbbVieSynthroid$19$2,02135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Easthampton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →